France· FR:62119207
BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée
A bezafibrate product containing bézafibrate, registered in France by ARROW GENERIQUES, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Bezafibrate is registered in 10 of 19 countries.
Countries holding a registration under ATC C10AB02 (bezafibrate), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 6 of them publish a price we can compare per daily dose
Bezafibrate · ATC C10AB02
10 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Franceprice
- Germany
- Italyprice
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of bezafibrate costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), the median price runs from $0.29 in France to $1.19 in Switzerland — a ×4.1 gap.
- France: $0.29 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Bezafibrate · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.19
- IT Italy$0.44
- FR France$0.29
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- BÉZAFIBRATE
- Manufacturer
- ARROW GENERIQUES
- Country
- France (FR)
- ATC code
- C10AB02
- ATC class
- Bezafibrate
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip133400932931491plaquette(s) PVC-Aluminium de 30 comprimé(s)EUR 6.4
- cip133400937177382plaquette(s) PVC-Aluminium de 90 comprimé(s)EUR 18.12
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bezafibrate in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomBezafibrate 400mg modified-release tabletsTeva UK Ltd
- FinlandBezafibrat GenericsGenerics (UK) Limited
- NetherlandsBezalip Retard 400 mg, tabletten met gereguleerde afgifteAurobindo Pharma B.V.
- NorwayBezalip RetardAurobindo Pharma
- CanadaBEZALIP SRALLERGAN INC
- SpainDIFATEROL RETARD 400 mg COMPRIMIDOS DE LIBERACION PROLONGADALaboratorios Bial S.A.
- SwedenBezalip Retard 400 mg DepottablettActavis Group PTC ehf.
- BelgiumEulitop 400 mgAurobindo
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Bezalip Retard, Bezastad
- Belgium · Cedur, Eulitop
- Cyprus · Lacromid, Zafibral
- Germany · Bezafibrat Al, Bezafibrat Retard Al
- Spain · Eulitop, Eulitop Retard
- Finland · Bezalip
- United Kingdom (Northern Ireland) · Bezafibrate, Bezafibrate Noumed Life Sciences
- Hungary · Bezalip
- Italy · Bezalip
- Luxembourg · Cedur, Eulitop
- Netherlands · Bezafibrate Aurobindo
- Portugal · Bezalip, Bezalip Retard
- Romania · Bezafibrat Arena
- Sweden · Bezalip, Bezalip Retard
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e836724b-6968-4efd-9ce0-6826a7e6b749 GET /v1/drugs/e836724b-6968-4efd-9ce0-6826a7e6b749?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62119207",
"date_amm": "1987-01-06",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "BÉZAFIBRATE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé enrobé à libération prolongée",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about bezafibrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.